Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase II Study of 5 Years of Adjuvant Osimertinib in EGFR-mutated NSCLC
2021-003024-33Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Nov 2022; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2021-003024-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003024-33.